Anti-CD44v9 Antibody-drug Conjugate AMT-116

**Semantic type:** Pharmacologic Substance

**Definition:** An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) CD44 variant 9 (CD44v9), linked to the topoisomerase I inhibitor (TOP1i) and belotecan derivative KL610023 via a hydrolysable linker, with potential antineoplastic activity. Upon intravenous administration of anti-CD44v9 ADC AMT-116, the monoclonal antibody moiety targets and binds to CD44v9 expressed on tumor cells. Upon binding and internalization, KL610023 is released. KL610023 targets and binds to DNA topoisomerase I, thereby inhibiting DNA replication and killing the CD44v9-expressing cancer cells. CD44v9, a splicing variant of CD44 overexpressed in numerous cancer cell types, is associated with tumorigenicity and cancer treatment resistance.

**Synonyms:** - ADC AMT-116 - AMT 116 - AMT-116 - AMT116 - Anti-CD44v9 ADC AMT-116